Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 3/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 11/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 11/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 8/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | GABRE | P78334 | 1/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205092 | 0.84 | HRH4 (0.56) | HRH4FLT3GABRA1GABRG2GABRB3 | |
| SCHEMBL28046328 | 0.83 | HRH4 (0.52) | HRH4FLT3GABRA1GABRG2GABRB3 | |
| SCHEMBL31513837 | 0.83 | HRH4 (0.52) | HRH4FLT3GABRA1GABRG2GABRB3 | |
| SCHEMBL30228606 | 0.82 | GABRA1 (0.45) | HRH4FLT3GABRA1GABRG2GABRB3 | |
| SCHEMBL3969314 | 0.81 | GABRA1 (0.44) | HRH4FLT3GABRA1GABRG2GABRB3 | |
| SCHEMBL2204502 | 0.80 | KDM4E (0.55) | HRH4FLT3GABRA1GABRG2GABRB3 | |
| SCHEMBL2440393 | 0.80 | HRH4 (0.52) | HRH4FLT3GABRA1GABRG2GABRB3 | |
| SCHEMBL31439894 | 0.79 | NPC1 (0.47) | HRH4FLT3KDM4EALDH1A1HSD17B10 | |
| SCHEMBL27893658 | 0.79 | GABRA1 (0.41) | HRH4FLT3GABRA1GABRG2GABRB3 | |
| SCHEMBL145350 | 0.77 | FLT3 (0.58) | HRH4FLT3KDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-7196103-B2 | Indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-27 | — | — | US | disclosed |
| CN-1283638-C | Indole-2-formamide compounds as factor Xa inhibitors | AVENTIS PHARMA GMBH (DE) | 2006-11-08 | — | — | CN | disclosed |
| EP-1633746-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-15 | — | — | EP | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| CN-1589270-A | Indole-2-formamide compounds as factor Xa inhibitors | AVENTIS PHARMA GMBH (DE) | 2005-03-02 | — | — | CN | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| US-20050033049-A1 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-10 | — | — | US | disclosed |
| WO-2004101554-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033049-A1 | Indole derivatives as factor Xa inhibitors | TFPI, TFPI2, F2 | HRH4 1888/4885FLT3 1092/4885GABRA1 3779/4885 |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | HRH4 471/4885FLT3 303/4885GABRA1 2986/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | HRH4 848/4885FLT3 693/4885GABRA1 3310/4885 |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | F12, F5, F2 | HRH4 626/4885FLT3 398/4885GABRA1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.